MW UPDATE: 23andMe is going public via a merger with Richard Branson's blank-check company
Ciara Linnane
New company will trade on the NYSE under ticker symbol 'ME'
23andMe, a consumer genetics company, is going public via a merger with Richard Branson's special-purpose acquisition corporation, or SPAC, VG Acquisition Corp., in a deal with an enterprise value of about $3.5 billion, the companies said Thursday.
SPACs, or blank-check companies, raise money in an initial public offering and then have two years to acquire a business or businesses. They have become a popular vehicle for IPOs during the pandemic, raising a record of $82 billion of proceeds in 2020, according to data provider Dealogic.
See also:2020 is the year of the SPAC -- yet traditional IPOs offer better returns, report finds
Once the deal has closed, the company will change its ticker symbol to "ME" and trade on the New York Stock Exchange.
23andMe co-Founder Anne Wojcicki and Branson, an early investor, are investing $25 million in the company, and will be joined by institutional investors including funds managed by Fidelity Management & Research Company LLC, Altimeter Capital, Casdin Capital and Foresite Capital.
The new company will have a pro forma cash balance of more than $900 million at closing. The deal is expected to close in the second quarter.
23andMe was founded in 2006 by Wojcicki, Linda Avey and Paul Cusenza and offers individuals the chance to have their genes tested, providing them with information on health risks and ancestry. Consumers can order one of the company's test kits, comprising a test tube for saliva collection that is then mailed to a laboratory for testing.
"Through a genetics-based approach, we fundamentally believe we can transform the continuum of health care.," Wojcicki said in a statement.
The Sunnyvale, California-based company's website says it has more than 12 million customers and more than 80% have opted to participate in research, allowing the company create one of the biggest genomic data sets in the world.
The company has to date collected 3 billion phenotypic data points and published more than 150 peer-reviewed studies in scientific journals.
Read also:The CEO who made one of Silicon Valley's worst acquisitions wants a $400 million blank check
The 23 in the name references the 23 pairs of chromosomes in human DNA.
VG Acquisition shares $(VGAC)$ rose 11% on the news.
Read also: A pandemic and now GameStop have turned young people on to investing. These top TikTok accounts offer advice for budding Warren Buffetts
-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com
$(END)$ Dow Jones Newswires
February 04, 2021 13:06 ET (18:06 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。